hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
=== De–Di === Christian de Duve FRS (foreign associate) (1917–2013). Belgian cytologist and biochemist at the Université Catholique de Louvain, known for discovering peroxisomes and lysosomes. Nobel Prize for Physiology or Medicine (1974). Foreign Associate Natl. Acad. Sci. USA. Michael W. Deem (PhD 1994). American biochemist and genetic engineer at Rice University, known for work in evolution, immunology, and materials. William DeGrado (b. 1955). American pharmaceutical chemist at UC San Francisco, known for protein design, synthesis of peptidomimetics, and characterizing membrane-active peptides and proteins. Member Natl. Acad. Sci. USA. Max Delbrück FRS (1906–1981). German-American biophysicist at Caltech. Nobel Prize in Physiology or Medicine (1969). Member Natl. Acad. Sci. USA. Hector DeLuca (b. 1930). American biochemist at the University of Wisconsin, known for work on vitamin D. Member Natl. Acad. Sci. USA. Pierre De Meyts (1944–2025). Belgian physician and biochemist at the Université Catholique de Louvain, known for studies of hormone-receptor interaction of peptide hormones and the physiopathogenesis of diabetes. Willey Glover Denis (1879–1929). American biochemist at Tulane University, a pioneer in clinical chemistry and the measurement of protein in biological fluids. Rosa Devés (born 1950), Chilean biochemist, first woman rector of the University of Chile. Richard E. Dickerson (1931–2025), American biochemist, the first to carry out a single-crystal structure analysis of B-DNA. Zacharias Dische (1895–1988).
A football pitch, or field, can be used as a man-in-the-street unit of area. The standard FIFA football pitch for international matches is 105 m (344 ft) long by 68 m (223 ft) wide (7,140 m2 or 0.714 ha or 1.76 acres); FIFA allows for a variance of up to 5 m (16.4 ft) in length in either direction and 7 m (23.0 ft) more or 4 m (13.1 ft) less in width (and larger departures if the pitch is not used for international competition), which generally results in the association football pitch generally only being used for order of magnitude comparisons. An American football field, including both end zones, is 360 by 160 ft (120.0 by 53.3 yd; 109.7 by 48.8 m), or 57,600 square feet (5,350 m2) (0.535 hectares or 1.32 acres). A Canadian football field is 65 yards (59 m) wide and 110 yards (100 m) long with end zones adding a combined 40 yards (37 m) to the length, making it 87,750 square feet (8,152 m2) or 0.8215 ha (2.030 acres). An Australian rules football field may be approximately 150 metres (160 yd) (or more) long goal to goal and 135 metres (148 yd) (or more) wide, although the field's elliptical nature reduces its area to a certain extent. A 150-by-135-metre (164 by 148 yd) football field has an area of approximately 15,900 m2 (1.59 ha; 3.9 acres), twice the area of a Canadian football field and three times that of an American football field.
As a salt, its dominant use is as an emulsifier for the emulsion polymerization of fluoropolymers such as PTFE, polyvinylidene fluoride, and fluoroelastomers. For this use, 3M subsidiary Dyneon has a replacement emulsifer despite DuPont stating PFOA is an "essential processing aid". In the past PFOA was used in the production of Gore-Tex as it is PTFE-based. In PTFE processing, PFOA is in aqueous solution and forms micelles that contain tetrafluoroethylene and the growing polymer. PFOA can be used to stabilize fluoropolymer and fluoroelastomer suspensions before further industrial processing and in ion-pair reversed-phase liquid chromatography it can act as an extraction agent. PFOA also finds uses in electronic products and as an industrial fluorosurfactant. In a 2009 EPA study of 116 products, purchased between March 2007 and May 2008 and found to contain at least 0.01% fluorine by weight, the concentrations of PFOA were determined. Concentrations shown below range from not detected, or ND, (with the detection limit in parentheses) to 6750 with concentrations in nanograms of PFOA per gram of sample (parts per billion) unless stated otherwise.
In addition to grains, such as corn, rice, or wheat, vegetable protein also occurs in legumes, which include beans and peanuts. Grains tend to be deficient in tryptophan and lysine, whereas legumes lack methionine Thus a meal combining grains and legumes such as the Mexican peasant dish of corn tortillas and refried beans is basically complete in amino acid content.
Sources: en.wikipedia.org
=== Genetic testing === Variations of the HLA-B gene increase the risk of developing ankylosing spondylitis, although it is not a diagnostic test. Those with the HLA-B27 variant are at a higher risk than the general population of developing the disorder, yet most individuals with the genetic marker do not develop AS. Thus, HLA-B27, demonstrated in a blood test, can help with diagnosis, but in itself is not diagnostic of AS in a person with back pain. Over 85% of people that have been diagnosed with AS are HLA-B27 positive, although this ratio varies from population to population: about 50% of African Americans with AS possess HLA-B27 in contrast to the figure of 80% among those with AS who are of Mediterranean descent. In Turkey, a study of 115 patients found 70% positivity for the HLA-B27 allele.
Amidorphin is an endogenous, C-terminally amidated, opioid peptide generated as a cleavage product of proenkephalin A in some mammalian species; in humans and most other species, the peptide is 1 residue longer and is not amidated. Amidorphin is widely distributed in the mammalian brain, with particularly high concentrations found in the striatum, and outside of the brain in adrenal medulla and posterior pituitary. The 26-residue peptide named amidorphin is found in several species including bovine (Bos taurus), sheep (Ovis aries), and pig (Sus scrofa). Humans and commonly studied lab animals (mice, rats) produce a 27-residue peptide that does not have an amidated C-terminal residue; this is due to the absence of a Gly in the precursor sequence and replacement with Ala, which is not a substrate for the amidating enzyme (Peptidyl-glycine alpha-amidating monooxygenase). The properties of the 27-residue peptide are presumably similar to those of amidorphin, although this has not been adequately tested. In some brain areas, amidorphin is extensively further reduced into smaller fragments, such as the non-opioid peptide amidorphin-(8-26), or in humans, amidorphin-8-27. Cleavage of amidorphin into these smaller fragments releases the N-terminal [Met]-enkephalin sequence of amidorphin.
Outfitting a scientific building with five laboratories full of the latest world-class specialised equipment such as biosafety cabinets, cold rooms, sterilisers and incubators was never going to be cheap or simple in a relatively remote location like Canberra, and much of the equipment had to be paid for in scarce US dollars.
Sources: en.wikipedia.org
=== Cardiovascular system === Nicotine exerts several significant effects on the cardiovascular system. Primarily, it stimulates the sympathetic nervous system, leading to the release of catecholamines. This activation results in an increase in heart rate and blood pressure, as well as enhanced myocardial contractility, which raises the workload on the heart. Additionally, nicotine causes systemic vasoconstriction, including constriction of coronary arteries, which can reduce blood flow to the heart. Long-term exposure to nicotine may impair endothelial function, potentially contributing to atherosclerosis. Furthermore, nicotine has been associated with the development of cardiac arrhythmias, particularly in individuals who already have underlying heart disease. The effects of nicotine can be differentiated between short-term and long-term use. Short-term nicotine use, such as that associated with nicotine replacement therapy (NRT) for smoking cessation, appears to pose little cardiovascular risk, even for patients with known cardiovascular conditions. In contrast, longer-term nicotine use may not accelerate atherosclerosis but could contribute to acute cardiovascular events in those with pre-existing cardiovascular disease. Many severe cardiovascular effects traditionally associated with smoking may not be solely attributable to nicotine itself. Cigarette smoke contains numerous other potentially cardiotoxic substances, including carbon monoxide and oxidant gases.
Arjo is a global medical technology company with an annual turnover of approximately €700 million, and 4,200 employees, serving the needs of acute and long-term care. The company produces medical equipment for patient handling and hygiene, medical beds and pressure ulcer prevention, wound healing, DVT & VTE prevention, disinfection and diagnostics
His reply to the votes of censure passed by the Assembly, and their refusal to increase his civil list was to hint at a vast communistic plot in order to scare the bourgeoisie, and to denounce the electoral law of 31 May 1850, in order to gain the support of the mass of the people. The Assembly retaliated by throwing out the proposal for a partial reform of that article of the constitution which prohibited the re-election of the president and the re-establishment of universal suffrage (July). All hope of a peaceful issue was at an end. When the questors called upon the Chamber to have posted in all barracks the decree of 6 May 1848 concerning the right of the Assembly to demand the support of the troops if attacked, the Mountain, dreading a restoration of the monarchy, voted with the Bonapartists against the measure, thus disarming the legislative power. Louis-Napoléon saw his opportunity, and organised the French coup of 1851. On the night of 1/2 December 1851, the anniversary of his uncle Napoleon's coronation in 1804 and his victory at Austerlitz in 1805, he dissolved the Chamber, re-established universal suffrage, had all the party leaders arrested, and summoned a new assembly to prolong his term of office for ten years. The deputies who had met under Berryer at the Mairie of the 10th arrondissement to defend the constitution and proclaim the deposition of Louis Napoleon were scattered by the troops at Mazas and Mont Valérien. The resistance organized by the republicans within Paris under Victor Hugo was soon subdued by the intoxicated soldiers.
=== Classification === Neanderthals can be classified as a unique species as H. neanderthalensis, though some authors argue expanding the definition of H. sapiens to include other ancient humans, with combinations such as H. sapiens neanderthalensis. The latter opinion has generally been justified using Neanderthal genetics, as well as inferences on the complexity of Neanderthal behaviour based on the archaeological record. While there seems to have been some genetic contact between these two groups, there are potential indicators of hybrid incompatibility, which if true could justify species distinction. The crux of the issue lies in the vagueness of the term "species" (the species problem). Among identified archaic humans, Neanderthals are most closely related to Denisovans based on nuclear DNA (nDNA) analyses. Denisovans are an enigmatic group of Late Pleistocene humans only recognisable by a genetic signature rather than anatomical landmarks. Likely due to more recent interbreeding episodes, the mitochondrial DNA (mtDNA, passed down maternally) and Y-chromosome DNA (passed down paternally) are more similar between Neanderthals and modern humans than between Neanderthals and Denisovans. Similarly, 430,000 year old fossils from the Sima de los Huesos are more closely related to Neanderthals in their nDNA, but their mtDNA aligns more closely with Denisovans. A 2021 phylogeny of some Middle Pleistocene and Neanderthal fossils using tip dating:
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.